Incyte (WBO:INCY) E10: €1.34 (As of Mar. 2026)


WBO:INCY Incyte Corp WBO:INCY
87 GF Score
Price €70.36
GF Value €61.46
! 4 Warning Signs
View Full Analysis

What is Incyte E10?

Incyte WBO:INCY 87 E10 is €1.34 as of Mar. 2026. GuruFocus rates WBO:INCY with a GF Score™ of 87/100 and a GF Value™ of €61.46. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Incyte's adjusted earnings per share data for the three months ended in Mar. 2026 was €1.272. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €1.34 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Incyte's average E10 Growth Rate was 67.30% per year. During the past 3 years, the average E10 Growth Rate was 46.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Incyte was 47.90% per year. The lowest was -14.20% per year. And the median was 10.90% per year.

As of today (2026-06-29), Incyte's current stock price is €70.36. Incyte's E10 for the quarter that ended in Mar. 2026 was €1.34. Incyte's Shiller PE Ratio of today is 52.51.

During the past 13 years, the highest Shiller PE Ratio of Incyte was 261.53. The lowest was 52.20. And the median was 76.81.


Incyte  (WBO:INCY) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Incyte's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=70.36/1.34
=52.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Incyte was 261.53. The lowest was 52.20. And the median was 76.81.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Incyte E10 Related Terms


Incyte E10 Historical Data

* Premium members only.

The historical data trend for Incyte's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte E10 Chart

Incyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.29 0.46 0.97 0.99 1.16

Incyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.24 1.32 1.27 1.16 1.34

WBO:INCY vs INSM, BNTX, ROIV: E10 Comparison

For the Biotechnology subindustry, Incyte's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incyte Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Incyte's Shiller PE Ratio falls into.


WBO:INCY
87GF Score
Incyte Corp WBO:INCY
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Incyte E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Incyte's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.272/330.2130*330.2130
=1.272

Current CPI (Mar. 2026) = 330.2130.

Incyte Quarterly Data

per share eps CPI Adj_EPS
201606 0.160 241.018 0.219
201609 0.169 241.428 0.231
201612 0.047 241.432 0.064
201703 -0.898 243.801 -1.216
201706 -0.053 244.955 -0.071
201709 0.143 246.819 0.191
201712 -0.600 246.524 -0.804
201803 -0.154 249.554 -0.204
201806 0.205 251.989 0.269
201809 0.120 252.439 0.157
201812 0.281 251.233 0.369
201903 0.416 254.202 0.540
201906 0.425 256.143 0.548
201909 0.536 256.759 0.689
201912 0.459 256.974 0.590
202003 -3.014 258.115 -3.856
202006 1.172 257.797 1.501
202009 -0.059 260.280 -0.075
202012 0.559 260.474 0.709
202103 0.202 264.877 0.252
202106 0.556 271.696 0.676
202109 0.697 274.310 0.839
202112 2.248 278.802 2.663
202203 0.154 287.504 0.177
202206 0.681 296.311 0.759
202209 0.505 296.808 0.562
202212 0.123 296.797 0.137
202303 0.093 301.836 0.102
202306 0.831 305.109 0.899
202309 0.712 307.789 0.764
202312 0.816 306.746 0.878
202403 0.690 312.332 0.730
202406 -1.895 314.175 -1.992
202409 0.487 315.301 0.510
202412 0.974 315.605 1.019
202503 0.740 319.799 0.764
202506 1.769 322.561 1.811
202509 1.798 324.800 1.828
202512 1.247 324.054 1.271
202603 1.272 330.213 1.272

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €1.34 mean?
Incyte (WBO:INCY) has a E10 of €1.34 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Incyte and its competitors.
Is Incyte's E10 too high?
Incyte's current E10 is €1.34. Overall, Incyte has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Incyte's E10 compare to INSM and BNTX?
Incyte's E10 of €1.34 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Incyte and its competitors. Incyte's current E10 is €1.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Incyte (WBO:INCY) has a current E10 of €1.34. The stock's GF Value™ is €61.46, compared to a current price of €70.36 — trading 14.5% above its estimated fair value. The current E10 is €1.34. Incyte's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Incyte (WBO:INCY), the current E10 is €1.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Incyte (WBO:INCY) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of €70.36 is trading 14.5% above its estimated GF Value™ of €61.46.

Key valuation signals for WBO:INCY:

  • E10: €1.34
  • GF Value™: €61.46 vs. price of €70.36 (14.5% above fair value)
  • GF Score™: 87/100 with 4 warning signs

No single metric tells the full story. See the WBO:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
87GF Score

Get the complete analysis for WBO:INCY

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€70.36
Price
€61.46
GF Value